Molecule intelOpportunity: Strong0Underserved

Recombinant Human Erythropoietin Alpha

4 brands · 2 companies · product forms

Opportunity snapshot

Launch attractiveness
51
Market saturation
6
Price room
75
Regulatory risk
0
4
brands
2
companies
Rs 19,268.72
median price
9
price points
3.99x
price spread
90
confidence %

Who competes here

Top companies by brand count — concentrated market · leader share 75%

3 brands · 75%
1 brands · 25%

Price room

Across observed sources and strengths
CheapestRs 10,437.23
MedianRs 19,268.72
Most expensiveRs 41,620.43
Spread3.99×
Sources: DRAP-official

max/min price ratio 3.99x across 9 trusted points (Rs 10437.23-41620.43). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Why this score

Launch attractiveness

40% supply-gap(40) + 25% price-variation(75) + 20% low-competition(94) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

2 canonical companies and 4 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 3.99x across 9 trusted points (Rs 10437.23-41620.43). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.